AnteoTech Ltd reported a 110% revenue increase to A$968,878 in FY2025 alongside a 24% reduction in net loss, driven by strategic cost savings and key partnerships. Leadership renewal and product validation position the company for growth in battery and life sciences markets.
- 110% revenue growth to A$968,878 in FY2025
- 24% reduction in net loss to A$6.76 million
- Strategic review delivers $1.6 million annualized cost savings
- Joint development agreement with Black Diamond Structures
- Five-year supply deal with Serum Institute of India
Financial Performance and Strategic Review
AnteoTech Ltd (ASX, ADO) has released its full-year results for the 12 months ended 30 June 2025, reporting a significant 110% increase in revenues to A$968,878. Despite this growth, the company remains loss-making, with a net loss after tax of A$6.76 million, although this represents a 24% improvement compared to the prior year’s A$8.88 million loss. The company attributes this progress to a comprehensive strategic review completed during the year, which yielded approximately A$1.6 million in annualized cost savings through organizational restructuring and a sharpened commercial focus.
Leadership Renewal and Market Positioning
FY2025 marked a leadership transition with Merrill Gray appointed as Managing Director and CEO in August 2025, following an interim period. Gray brings extensive experience in critical minerals and battery supply chains, particularly in Europe and the automotive sector, signaling AnteoTech’s intent to deepen its commercial expertise and accelerate market engagement. The Board also welcomed Glenda McLoughlin as Chair, reinforcing governance with seasoned investment banking and energy sector expertise.
Commercial Milestones and Product Validation
AnteoTech’s Advanced Battery Technologies business achieved notable technical milestones, including the validation of its Ultranode™ high-silicon anode technology with Swiss miniature battery manufacturer Wyon AG. The company also signed a binding term sheet for a joint development agreement with US-based Black Diamond Structures to co-develop a next-generation lithium-ion battery additive incorporating AnteoTech’s patented AnteoX™ cross-linker. These developments underscore the company’s commitment to commercializing high-performance, sustainable battery materials.
In the Life Sciences segment, AnteoTech secured a five-year supply agreement with the Serum Institute of India, the world’s largest vaccine manufacturer, with orders exceeding contractual minimums in the first year. The company continues to expand its diagnostic product pipeline, including the launch of AnteoBind NXT™, which offers improved performance and cost efficiencies for diagnostic test developers.
Capital and Funding
AnteoTech strengthened its balance sheet during FY2025, raising A$4.3 million through a share placement and entitlement offer priced at 2.0 cents per share. Additionally, the company secured a nearly A$4 million grant from the Australian Renewable Energy Agency (ARENA) to support its battery technology development projects. Cash on hand stood at A$2.34 million at year-end, supplemented by a subsequent A$2.59 million R&D tax rebate received in August 2025.
Outlook and Market Expansion
Looking ahead, AnteoTech is focused on scaling sales globally across its battery and life sciences product lines, with targeted expansion in the USA, South Korea, India, Europe, and Japan. The company aims to leverage strategic partnerships to accelerate commercialization, particularly for its Ultranode™ products in electric vehicle and consumer battery markets. The Life Sciences unit plans to deepen engagements in India and explore new applications in animal health and biosecurity diagnostics.
While the company remains loss-making, the combination of technical validation, strategic partnerships, leadership renewal, and cost discipline positions AnteoTech to capitalize on growing demand for advanced battery materials and diagnostic solutions.
Bottom Line?
AnteoTech’s FY2025 results set the stage for a pivotal growth phase, but sustained commercialization and capital management will be critical to turning innovation into profitability.
Questions in the middle?
- How quickly can AnteoTech convert its strategic partnerships into recurring revenue streams?
- What are the timelines and milestones for scaling production of Ultranode™ and AnteoX™ products?
- How will the company manage ongoing losses while expanding its global sales footprint?